evenamide (NW-3509) / Newron 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evenamide (NW-3509) / Newron
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia.

Ongoing
2/3
196
Europe, RoW
Evenamide, NW3509, Capsule, hard
Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A
Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-002093-34: Phase II / III, open-label, extension study designed to determine the long-term safety, tolerability and efficacy of evenamide (NW-3509) in patients with psychiatric disorders who participated in previous trials with evenamide. Studio di fase II/III, di estensione, in aperto, progettato per determinare la sicurezza a lungo termine, la tollerabilità e l'efficacia di evenamide (NW-3509) in pazienti con disturbi psichiatrici che hanno partecipato a precedenti studi con evenamide.

Not yet recruiting
2/3
500
Europe
Evenamide, [NW3509], Capsule, hard
NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A
Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-000437-41: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients with treatment-resistant schizophrenia (TRS). Studio multicentrico pilota, in aperto, randomizzato, per valutare sicurezza, tollerabilità ed efficacia preliminare in tre gruppi paralleli con tre dosi fisse di Evenamide somministrate come terapia aggiuntiva a pazienti affetti da schizofrenia resistente al trattamento (TRS).

Not yet recruiting
2
150
Europe
Evenamide, [NW-3509], Capsule, hard
NEWRON PHARMACEUTICALS SPA
Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-000439-32: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. Studio di estensione in aperto, multicentrico per valutare sicurezza, tollerabilità ed efficacia preliminare a lungo termine di evenamide come terapia aggiuntiva in pazienti affetti da schizofrenia resistente al trattamento (TRS) che non rispondono adeguatamente al farmaco antipsicotico attualmente in corso

Not yet recruiting
2
150
Europe
Evenamide, [NW-3509], [NE-3509], Capsule, hard
NEWRON PHARMACEUTICALS SPA
Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 

Download Options